Gene Panel Versus Whole Exome Sequencing for Fetal Anomalies
Prenatal Diagnosis · 2026-05 · 46 (5-6) · 643-649
DOI: 10.1002/pd.70118 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Prenatal Diagnosis, online erschienen am 12.03.2026. Verfasst von Kate Swanson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of California, San Francisco, Califo…. Hauptthemen laut MEDLINE: Exome Sequencing, Genetic Testing, Congenital Abnormalities, Prenatal Diagnosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: NHGRI NIH HHS, National Human Genome Research Institute.
Abstract (Originalsprache)
Objective
Exome sequencing (ES) and gene panels can be considered for fetal anomalies. Whether ES offers substantial benefit over targeted panels is not clear.
Methods
Secondary analysis of a prospective cohort study of pregnancies with fetal anomalies undergoing ES. We included cases with isolated or multisystem skeletal dysplasias, CNS anomalies, and/or cardiac anomalies. Participants underwent ES, and pathogenic (P) and likely pathogenic (LP) variants were reported. The primary outcome was the percentage of P/LP variants found on ES that would have been identified on panels available prenatally in the United States.
Results
109 cases with relevant anomalies were included in the primary analysis. Of these, 20 (18%) had P/LP variant(s) identified on ES—4 multisystem, 4 isolated CNS, 6 isolated cardiac, and 6 isolated skeletal dysplasia. Gene panels would have detected 50 (88%) of the variants identified by ES. Yield was highest for isolated skeletal anomalies (100%) compared to CNS and cardiac malformations (75% and 67%, p = 0.02). Yield was higher for isolated anomalies than multisystem anomalies (median 91.5% vs. 50%, p < 0.01).
Conclusions
In cases of fetal anomalies with genetic etiologies identified on ES, commercial gene panels had variable diagnostic yields. Panels performed worst for multisystem anomalies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of California, San Francisco, California, USA.
- Department of Pediatrics, Division of Medical Genetics, University of California, San Francisco, California, USA.
- Department of Obstetrics & Gynecology, Division of Maternal-Fetal Medicine, Intermountain Healthcare, Salt Lake City, Utah, USA.
- Center for Maternal-Fetal Precision Medicine, University of California, San Francisco, California, USA.
- Institute for Human Genetics, University of California, San Francisco, California, USA.
ORCID-Profile: Kate Swanson, Teresa N Sparks, Billie R Lianoglou
Förderung
- NHGRI NIH HHS
- National Human Genome Research Institute
Zitieren
APA
Swanson, K., Shear, M. A., Sparks, T. N., Sahin-Hodoglugil, N. N., Lianoglou, B. R., & Norton, M. E. (2026). Gene Panel Versus Whole Exome Sequencing for Fetal Anomalies. Prenatal Diagnosis, 46(5-6), 643-649. https://doi.org/10.1002/pd.70118
Vancouver
Swanson K, Shear MA, Sparks TN, Sahin-Hodoglugil NN, Lianoglou BR, Norton ME. Gene Panel Versus Whole Exome Sequencing for Fetal Anomalies. Prenatal Diagnosis. 2026;46(5-6):643-649. doi:10.1002/pd.70118
BibTeX
@article{Swanson2026,
author = {Swanson, Kate and Shear, Matthew A and Sparks, Teresa N and Sahin-Hodoglugil, Nuriye N and Lianoglou, Billie R and Norton, Mary E},
title = {Gene Panel Versus Whole Exome Sequencing for Fetal Anomalies},
journal = {Prenatal Diagnosis},
year = {2026},
volume = {46},
number = {5-6},
pages = {643--649},
doi = {10.1002/pd.70118}
}
EUVIMED